supplementary Figures S1-S10 from Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer
posted on 2023-03-30, 23:28authored byPiergiorgio Pettazzoni, Andrea Viale, Parantu Shah, Alessandro Carugo, Haoqiang Ying, Huamin Wang, Giannicola Genovese, Sahil Seth, Rosalba Minelli, Tessa Green, Emmet Huang-Hobbs, Denise Corti, Nora Sanchez, Luigi Nezi, Matteo Marchesini, Avnish Kapoor, Wantong Yao, Maria E. Di Francesco, Alessia Petrocchi, Angela K. Deem, Kenneth Scott, Simona Colla, Gordon B. Mills, Jason B. Fleming, Timothy P. Heffernan, Philip Jones, Carlo Toniatti, Ronald A. DePinho, Giulio F. Draetta
supplementary Figures S1-S10. S1 growth and regression of iKRAS tumors. S2 culture comparison. S3 immunohistochemistry of p-erk and p-s6 S4 Phospho rtk array S5 Validation of anti AXL antibodies S6 validationn of the AXL inhibitor in vitro S7 validationn of the AXL inhibitor in vivo S8 efficacy of targeting AXL S9 RTK array of iKRAS cells treated with multiple RTK inhibitors S10 P-ERK levels